XML 140 R123.htm IDEA: XBRL DOCUMENT v3.24.0.1
Quarterly Results of Operations (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2023
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Quarterly Financial Data [Abstract]                      
Revenue $ 556,055 $ 511,015 $ 469,136 $ 427,690 $ 382,432 $ 352,585 $ 319,939 $ 297,057      
Total operating expenses 577,405 528,953 490,704 438,045 384,310 339,634 324,572 299,855      
Loss before preferred dividends and accretion of Series A Preferred Stock (33,411) (25,324) (34,323) (19,982)         $ (113,040) $ (19,164) $ (37,601)
Dividends and accretion of Series A Preferred Stock (7,984) (7,872) (7,088) (6,276)         (29,220) 0 0
Loss from continuing operations         (11,349) 2,123 (4,125) (5,350)      
Dividends and accretion of Series A Preferred Stock         0 0 (463) 0      
Net (loss) attributable to common shareholders of Evolent Health, Inc. - Basic (41,395) (33,196) (41,411) (26,258) (11,349) 2,123 (4,588) (5,350) (142,260) (19,164) (37,601)
Net (loss) attributable to common shareholders of Evolent Health, Inc., Inc. - Diluted $ (41,395) $ (33,196) $ (41,411) $ (26,258) $ (11,349) $ 2,123 $ (4,588) $ (5,350) $ (142,260) $ (19,164) $ (37,601)
Loss per common share                      
Basic (in dollars per share) $ (0.36) $ (0.30) $ (0.37) $ (0.24) $ (0.11) $ 0.02 $ (0.05) $ (0.06) $ (1.28) $ (0.20) $ (0.44)
Diluted (in dollars per share) $ (0.36) $ (0.30) $ (0.37) $ (0.24) $ (0.11) $ 0.02 $ (0.05) $ (0.06) $ (1.28) $ (0.20) $ (0.44)